NDA 022134 · Abbvie
Lastacaft
Alcaftadine · Ophthalmic · Histamine-1 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Aug 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jul 28, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
907
133 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 10, 2022.
Us e temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 10, 2021 Supplement 8 · Efficacy LabelLetter
- Jul 28, 2010 Original approval · Type 1 - New Molecular Entity NovelPediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
1 products under this application
- LASTACAFT · ALCAFTADINE 0.25% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Alcaftadine" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic ConjunctivitisPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01732757 · 157 participants · Start Nov 2012 · Primary completion Dec 2012
Drug: Alcaftadine 0.25%; Olopatadine 0.2% and 1 more · For: Conjunctivitis, Allergic
Sites: Memphis, Tennessee
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic ConjunctivitisPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT01470118 · 127 participants · Start Oct 2011 · Primary completion Dec 2011
Drug: alcaftadine 0.25% ophthalmic solution; olopatadine 0.2% ophthalmic solution and 1 more · For: Conjunctivitis, Allergic
Sites: Philadelphia, Pennsylvania
- Safety and Efficacy Study of a Eye Drop for Eye AllergyPivotal-lookingCompleted
Vistakon PharmaceuticalsIndustry
NCT00889330 · 60 participants · Start Apr 2009 · Primary completion May 2009
Drug: alcaftadine; Placebo · For: Allergic Conjunctivitis
Sites: Fairfield, Ohio; Mason, Ohio
- Ocular Allergy Treatment Practical Impact TrialStatus unknown
Starx Research Center, LLCIndustry
NCT01808768 · 50 participants (planned) · Start Apr 2013 · Primary completion Oct 2013
Drug: Alcaftadine · For: Allergic Conjunctivitis; Rhinoconjunctivitis
Sites: Edison, New Jersey; Springfield, New Jersey
- Comparison of Tolerability Between Two Allergy DropsStatus unknown
Hom, Milton M., OD, FAAOIndividual
NCT01390961 · 48 participants (planned) · Start Aug 2011 · Primary completion Dec 2011
Drug: alacaftadine and naphazoline HCl & pheniramine maleate · For: Allergic Conjunctivitis
Sites: Azusa, California
ORA, Inc.Industry
NCT02308501 · 25 participants · Start Dec 2014 · Primary completion Feb 2015
Drug: Lastacaft ®; Tears Naturale ® (Placebo) · For: Allergic Conjunctivitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ocular hyperaemia299
- eye irritation171
- eye pain103
- eye pruritus103
- eye swelling84
- drug ineffective65
- hypersensitivity64
- lacrimation increased57
- eye discharge47
- eyelid oedema42
- erythema of eyelid39
- conjunctivitis38
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 60 |
| 2012 | 138 |
| 2013 | 66 |
| 2014 | 163 |
| 2015 | 83 |
| 2016 | 49 |
| 2017 | 18 |
| 2018 | 19 |
| 2019 | 30 |
| 2020 | 19 |
| 2021 | 17 |
| 2022 | 21 |
| 2023 | 104 |
| 2024 | 67 |
| 2025 | 37 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.
Fujishima H, Hasunuma T, Kawakita T, et al. · Ocul Immunol Inflamm 2021 · Clinical Trial, Phase III, Comparative Study
- Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S, Sridhar S, Kumar K, et al. · Indian J Ophthalmol 2021 · Randomized Controlled Trial
- Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study.
Nakatani H, Gomes P, Bradford R, et al. · Ocul Immunol Inflamm 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L, Janakiraman A, Dudeja I, et al. · Indian J Ophthalmol 2019 · Randomized Controlled Trial
- The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.
Torkildsen G, Shedden A · Curr Med Res Opin 2011 · Clinical Trial, Phase III, Multicenter Study
- Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.
McLaurin EB, Marsico NP, Ackerman SL, et al. · Adv Ther 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.